Table 3 Dose adjustments

Day 1 and 15 lab values		Irinotecan (%)	Oxaliplatin (%)	Uft (%)
Bilirubin ^a	ALP ^a
<1.5 × n	<5 × n	100	100	100
1.5–3 × n	>5 × n	50	100	Omit
>3 × n	—	Omit	Omit	Omit
Cockcroft (GFR; ml min⁻¹)^b
>50		100	100	100
30–50		100	50	100
<30		50	Omit	1 cap reduction^c

^aDeteriorating liver function during treatment could indicate progressive disease or biliary obstruction and was investigated by ultrasound examination.
^bDeteriorating renal function during treatment could indicate progressive pelvic disease and ureteric obstruction and was investigated by ultrasound examination.
^cUFT is available in 100 mg capsules. All calculated doses were rounded to the nearest no. of capsules.

Quick links

Search